Results for tag: "Myelodysplastic Syndrome"

Myelodysplastic Syndrome (MDS) is a group of hematological disorders characterized by ineffective production of blood cells in the bone marrow. It is caused by a variety of genetic and environmental factors, and is often associated with a history of chemotherapy or radiation therapy. Symptoms of MDS include fatigue, shortness of breath, easy bruising, and frequent infections. Treatment options include supportive care, chemotherapy, and stem cell transplantation. The MDS market is a rapidly growing segment of the hematology market, driven by increasing prevalence of the disease, rising awareness, and the availability of new treatments. The market is expected to witness significant growth in the coming years, due to the increasing number of clinical trials and the development of novel therapies. Some of the key players in the MDS market include Celgene Corporation, Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, and Amgen Inc. Show Less Read more